A phase II study of ¹8F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.

O'Brien, M E R; Myerson, J S; Coward, J I G; Puglisi, M; Trani, L; Wotherspoon, A; Sharma, B; Cook, G; Ashley, S; Gunapala, R; Chua, S; Popat, S

O'Brien, M E R; Myerson, J S; Coward, J I G; Puglisi, M; Trani, L; Wotherspoon, A; Sharma, B; Cook, G; Ashley, S; Gunapala, R; Chua, S; Popat, S.

Affiliation

O'Brien ME; Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom.

Eur J Cancer ; 48(1): 68-74, 2012 Jan.

Article in En | MEDLINE | ID: mdl-22119198

Subject(s)

Carcinoma, Non-Small-Cell Lung/diagnostic imaging; Carcinoma, Non-Small-Cell Lung/drug therapy; Fluorodeoxyglucose F18; Lung Neoplasms/diagnostic imaging; Lung Neoplasms/drug therapy; Quinazolines/therapeutic use; Tomography, Emission-Computed; Adult; Aged; Aged, 80 and over; Antineoplastic Agents/adverse effects; Antineoplastic Agents/therapeutic use; Biomarkers, Pharmacological/analysis; Carcinoma, Non-Small-Cell Lung/mortality; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms/mortality; Male; Middle Aged; Phenotype; Positron-Emission Tomography; Quinazolines/adverse effects; Time Factors; Tomography, Emission-Computed/methods; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Tomography, Emission-Computed / Carcinoma, Non-Small-Cell Lung / Fluorodeoxyglucose F18 / Lung Neoplasms Type of study: Diagnostic_studies / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Eur J Cancer Year: 2012 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google